THE LONG GAME
SoulSpring Wellness Journal™
Volume 01 · Issue 05
What Happens When GLP-1 Use Becomes Long-Term?
There is a question I think we need to ask before we close this conversation.
Not just:
Does it work?
Not just:
How much weight can I lose?
But:
What happens next?
Because GLP-1 medications have become part of the conversation around weight loss in a very big way.
And for some people, they have been genuinely life-changing.
People have lost significant amounts of weight. Blood sugar has improved. Health markers have changed. Some people feel like they have finally found something that helps them after years of struggling.
Those things matter.
But after everything we have explored throughout this series, I think we also need to look further ahead.
Because weight loss is one chapter.
The long game is another.
SO, IS THIS A TEMPORARY MEDICATION?
For many people, that may be one of the first questions they ask.
How long will I need to take this?
Six months?
A year?
Until I reach my goal weight?
And what happens after that?
The reality is that obesity medications are increasingly viewed as treatments for a chronic condition, and current medical guidance recognizes that continuing treatment may be necessary to maintain the benefits achieved.
And that changes the conversation.
Because this may not simply be about taking something until you lose the weight.
For some people, the question may eventually become:
Am I prepared to take this for years?
WHAT HAPPENS WHEN YOU STOP?
This is one of the biggest questions surrounding these medications.
And the research we have so far is clear about one thing.
Weight regain is common after treatment ends.
In the STEP 1 extension trial, participants who had taken semaglutide regained approximately two-thirds of the weight they had lost within one year of stopping treatment. Many of the improvements in cardiometabolic markers also moved back toward baseline after the medication was discontinued.
That doesn’t mean everyone will regain the same amount of weight.
Bodies are different.
Circumstances are different.
But it does mean that stopping the medication is not necessarily as simple as reaching a goal weight and moving on.
AND THAT BRINGS UP AN IMPORTANT QUESTION.
If someone begins a medication believing it will be temporary…
But later discovers that maintaining the benefits may require continued treatment…
Was that part of the original conversation?
Was there a discussion about what long-term treatment might look like?
The ongoing cost?
The potential side effects?
The monitoring?
The nutritional considerations?
What happens if insurance stops covering it?
What happens if the medication becomes unavailable?
What happens if a person simply decides they don’t want to take it anymore?
These aren’t reasons to avoid the medication.
They are questions people deserve to ask before they start.
WHAT HAPPENS TO THE BODY OVER TIME?
This is where I think the long game becomes especially important.
Because weight loss alone does not tell us what is happening to body composition.
Throughout this series, we have already talked about muscle and lean mass.
And that conversation does not become less important just because treatment becomes long-term.
Current research suggests that while GLP-1-based therapies primarily reduce fat mass, they can also produce reductions in lean mass or lean soft tissue.
Researchers are increasingly focused on how to preserve muscle, physical function, nutritional adequacy, and bone health during significant medication-assisted weight loss.
This matters for everyone.
But it may matter even more as we age.
Especially in midlife.
Especially for women.
Especially during and after menopause.
Because muscle is not just something that affects the way our bodies look.
It affects how we move.
Our strength.
Our stability.
Our metabolism.
Our independence.
And the quality of our lives as we get older.
So if GLP-1 use becomes a long-term part of someone’s life, I think body composition needs to be part of the conversation too.
Not just weight.
What are we losing?
And what are we actively protecting?
ARE WE EATING ENOUGH?
GLP-1 medications are designed to reduce appetite.
That’s part of how they work.
But when appetite is significantly reduced for a long period of time, another question naturally follows.
Are we still getting enough of what our bodies need?
Enough protein?
Enough vitamins and minerals?
Enough fluids?
Enough fiber?
Enough calories to support the body while still losing weight?
A smaller appetite does not automatically mean a person’s nutritional needs become smaller.
And when someone is eating significantly less, the quality of what they are eating may become even more important.
This is one of the areas where long-term care matters.
Because medication may suppress appetite.
But it does not replace nutrition.
WHAT ABOUT BONE HEALTH?
Bone health is another part of the conversation that deserves attention.
Especially during significant or rapid weight loss.
Especially for women approaching or living through menopause.
And especially when treatment is expected to continue long-term.
Researchers are continuing to study how GLP-1-based weight loss affects bone health, body composition, and physical function over time.
Current reviews emphasize the need to look beyond the number on the scale and monitor the quality of weight loss, including lean mass and musculoskeletal health.
Again, this doesn’t mean the medication automatically causes osteoporosis.
It means the long game requires us to pay attention to more than weight.
WHAT IF YOU NEED TO STAY ON IT?
This is where I think the conversation gets very real.
What happens when the medication works?
What happens when you feel better?
What happens when you lose the weight?
And then you realize that stopping may mean gaining much of it back?
For some people, continuing medication may be the right choice.
For others, it may not be.
But either way, that is a significant decision.
Long-term medication means ongoing access.
Ongoing medical care.
Ongoing monitoring.
And potentially, ongoing financial cost.
The long game isn’t just biological.
It’s practical.
It’s financial.
It’s emotional.
It’s about whether long-term treatment is actually sustainable for the individual taking it.
WE ALSO HAVE TO TALK ABOUT THE STOP-START CYCLE.
People don’t always discontinue a medication because they want to.
Sometimes insurance changes.
Sometimes the cost becomes too high.
Sometimes there are shortages.
Sometimes the side effects become too difficult.
And sometimes people simply decide they are done.
But starting and stopping treatment may create its own challenges.
Weight and metabolic markers can fluctuate significantly when treatment is interrupted.
And while researchers continue to study the long-term consequences of repeatedly starting, stopping, and restarting GLP-1-based medications, there are still things we don’t know.
The fact that a medication is widely prescribed today does not mean we already have every answer about decades of use.
ARE WE LOOKING FAR ENOUGH AHEAD?
This may be the question underneath this entire series.
Are we looking far enough ahead?
We know these medications can produce significant weight loss.
We know they can improve important health outcomes for some people.
We also know they can cause side effects.
We know serious complications can occur.
We know weight regain is common after discontinuation.
And we know that many of the questions surrounding long-term use are still being answered.
So perhaps we need to stop treating the decision to begin a GLP-1 medication as simply a decision about losing weight.
Maybe it is also a decision about:
What happens to my body during the process?
What am I doing to protect my muscle?
How am I nourishing myself?
How will my health be monitored?
How long am I willing or able to take this medication?
What happens if I need to stop?
What happens if I want to stop?
And what does my life look like after the number on the scale has changed?
THE SOULSPRING PERSPECTIVE
After five issues, this is where I land.
I don’t believe there is one answer that applies to everyone.
And I don’t believe every concern about these medications should be dismissed as fearmongering.
People deserve information.
The good.
The bad.
The benefits.
The risks.
What we know.
And what we still don’t know.
Because a decision about medication should never be based solely on the promise of a smaller body.
It should include the whole picture.
Your health.
Your nutrition.
Your strength.
Your muscle.
Your digestion.
Your mental and emotional well-being.
Your finances.
Your lifestyle.
And your ability to realistically sustain whatever path you choose.
That is the long game.
And maybe that is the biggest question of all.
Are we choosing something we can live with?
Not just until we reach a certain number.
But beyond it.
SOURCES
American Diabetes Association Professional Practice Committee. “8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes, 2026.” Diabetes Care, vol. 49, Supplement 1, 2026. The American Diabetes Association recommends that obesity pharmacotherapy intended for chronic treatment be continued beyond achieving weight-loss goals when appropriate, noting that discontinuation is often followed by recurrent weight gain and worsening cardiometabolic risk factors.
Wilding, John P. H., Rachel L. Batterham, Melanie Davies, et al., and the STEP 1 Study Group. “Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension.” Diabetes, Obesity and Metabolism, vol. 24, no. 8, 2022, pp. 1553-1564. DOI: 10.1111/dom.14725. This trial extension examined what happened after semaglutide treatment was discontinued and found that participants regained approximately two-thirds of their previous weight loss within one year, while many cardiometabolic improvements moved back toward baseline.
West, Sam, Jadine Scragg, Paul Aveyard, et al. “Weight Regain After Cessation of Medication for Weight Management: Systematic Review and Meta-Analysis.” The BMJ, vol. 392, 2026, e085304. DOI: 10.1136/bmj-2025-085304. This systematic review and meta-analysis examined weight regain after stopping weight-management medications and found that weight regain was common and often rapid, with improvements in cardiometabolic markers tending to reverse following cessation.
Trajectory of Weight Regain After Cessation of GLP-1 Receptor Agonists: A Systematic Review and Nonlinear Meta-Regression. 2026. This systematic review analyzed 48 studies and found consistent weight regain following GLP-1 receptor agonist cessation. Its analysis estimated that approximately 60% of weight lost during treatment had been regained one year after stopping.
Ceriello, Antonio, Francesco Prattichizzo, Abdul Raouf Mastan Sheik Abdullah, et al. “Causes and Consequences of Discontinuation of GLP1RAs or Tirzepatide.” Nature Reviews Endocrinology, vol. 22, 2026, pp. 530-542. This review examined reasons people discontinue GLP-1 receptor agonists and tirzepatide, including adverse effects, cost, and treatment effectiveness, as well as the common consequences of discontinuation, including weight regain and deterioration of cardiometabolic measures.
Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.Nutrients, 2026. This review examined body-composition changes during GLP-1-based treatment and discussed strategies for preserving lean mass, physical function, nutritional adequacy, and bone health during medication-assisted weight loss.
JACC: Advances Expert Panel. “Obesity Pharmacotherapy: An Urgent Need for Progressing Science, Access, and Equity.” JACC: Advances, 2026. This expert panel discussed unresolved questions surrounding the long-term management of obesity, including duration of treatment, discontinuation, weight regain, body composition, lean skeletal muscle loss, and physical function.
A NOTE FROM SOULSPRING
Thank you for joining us for Volume 01 · Issue 05 of the SoulSpring Wellness Journal™.
This issue brings our five-part GLP-1 series to a close.
Our intention throughout this series has never been to tell anyone what they should do with their body.
It has been to make room for the questions.
The ones that deserve more than a headline.
More than a social media trend.
More than a before-and-after photo.
We believe people deserve to understand the full picture before making decisions about their health.
And sometimes the most important questions are the ones we don’t think to ask until later.
So as this series comes to a close, I hope it leaves you with one thing.
Keep asking questions.
Ask about the benefits.
Ask about the risks.
Ask about what happens now.
And ask about what happens next.
Because the long game matters.
Until next time,
SoulSpring Oasis
IMPORTANT NOTE
This article is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It should not be considered medical advice or a substitute for individualized medical care. Always consult a qualified healthcare professional regarding medications, symptoms, side effects, nutrition, and decisions related to your personal health. Never stop or change a prescribed medication without speaking with your healthcare provider first.
